{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:39:45Z","timestamp":1773769185666,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ecl.2013.05.009","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T23:46:22Z","timestamp":1378338382000},"page":"489-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Type 2 Diabetes and Cognitive Compromise"],"prefix":"10.1016","volume":"42","author":[{"given":"Efrat","family":"Kravitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Schmeidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Schnaider Beeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2013.05.009_bib1","unstructured":"Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. 2011. Available at: http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheet11.htm. Accessed March 21, 2013."},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","article-title":"2013 Alzheimer's disease facts and figures","volume":"9","author":"Alzheimer\u2019s Association","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.ecl.2013.05.009_bib3","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","article-title":"Cognitive decline and dementia in diabetes\u2013systematic overview of prospective observational studies","volume":"48","author":"Cukierman","year":"2005","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2337\/db06-0879","article-title":"The effect of borderline diabetes on the risk of dementia and Alzheimer's disease","volume":"56","author":"Xu","year":"2007","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2337\/diabetes.53.2.474","article-title":"Increased risk of type 2 diabetes in Alzheimer disease","volume":"53","author":"Janson","year":"2004","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2013.05.009_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7326\/0003-4819-153-3-201008030-00260","article-title":"National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline","volume":"153","author":"Daviglus","year":"2010","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JAD-2006-10113","article-title":"Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease","volume":"10","author":"de la Monte","year":"2006","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000265552","article-title":"Diabetes is associated with increased rate of cognitive decline in questionably demented elderly","volume":"29","author":"Ravona-Springer","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"10.1016\/j.ecl.2013.05.009_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.61.5.661","article-title":"Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function","volume":"61","author":"Arvanitakis","year":"2004","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib10","first-page":"27","article-title":"Cognitive performance of Canadian seniors","volume":"22","author":"Gilmour","year":"2011","journal-title":"Health Rep"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.160.2.174","article-title":"Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group","volume":"160","author":"Gregg","year":"2000","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1017\/S1355617704104165","article-title":"Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study","volume":"10","author":"Hassing","year":"2004","journal-title":"J\u00a0Int Neuropsychol Soc"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ageing\/afh100","article-title":"Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study","volume":"33","author":"Hassing","year":"2004","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1212\/WNL.56.1.42","article-title":"Cardiovascular risk factors and cognitive decline in middle-aged adults","volume":"56","author":"Knopman","year":"2001","journal-title":"Neurology"},{"issue":"7439","key":"10.1016\/j.ecl.2013.05.009_bib15","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/bmj.37977.495729.EE","article-title":"Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years","volume":"328","author":"Logroscino","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1874609811205020131","article-title":"Cognition in non-demented diabetic older adults","volume":"5","author":"Nandipati","year":"2012","journal-title":"Curr Aging Sci"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3233\/JAD-2012-120106","article-title":"Changes in glycemic control are associated with changes in cognition in non-diabetic elderly","volume":"30","author":"Ravona-Springer","year":"2012","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.ecl.2013.05.009_bib18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00125-006-0333-1","article-title":"The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study","volume":"49","author":"van den Berg","year":"2006","journal-title":"Diabetologia"},{"issue":"17","key":"10.1016\/j.ecl.2013.05.009_bib19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1212\/WNL.0b013e3181bd80e9","article-title":"Diabetes is associated with a slower rate\u00a0of cognitive decline in Alzheimer disease","volume":"73","author":"Sanz","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1464-5491.2011.03445.x","article-title":"Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real.FR cohort","volume":"29","author":"Sanz","year":"2012","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.ecl.2013.05.009_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archneur.64.4.570","article-title":"Relation of diabetes to mild cognitive impairment","volume":"64","author":"Luchsinger","year":"2007","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.ecl.2013.05.009_bib23","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1212\/01.WNL.0000144281.38555.E3","article-title":"Vascular risk factors, incidence of MCI, and rates of progression to dementia","volume":"63","author":"Solfrizzi","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/01.WNL.0000134666.64593.BA","article-title":"Diabetes, impaired fasting glucose, and development of cognitive impairment in older women","volume":"63","author":"Yaffe","year":"2004","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ecl.2013.05.009_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archneur.65.8.1066","article-title":"Association of duration and severity of diabetes mellitus with mild cognitive impairment","volume":"65","author":"Roberts","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ecl.2013.05.009_bib26","series-title":"Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"issue":"10","key":"10.1016\/j.ecl.2013.05.009_bib27","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1212\/01.WNL.0000144278.79488.DD","article-title":"Diabetes mellitus in midlife and the risk of dementia three decades later","volume":"63","author":"Schnaider Beeri","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ecl.2013.05.009_bib28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1749-6632.1997.tb48496.x","article-title":"The risk of dementia among persons with diabetes mellitus: a population-based cohort study","volume":"826","author":"Leibson","year":"1997","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.ecl.2013.05.009_bib29","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: The Rotterdam Study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2337\/diabetes.51.4.1256","article-title":"Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study","volume":"51","author":"Peila","year":"2002","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/01.WNL.0000149519.47454.F2","article-title":"Midlife cardiovascular risk factors and risk of dementia in late life","volume":"64","author":"Whitmer","year":"2005","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ecl.2013.05.009_bib32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1212\/01.WNL.0000140291.86406.D1","article-title":"Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study","volume":"63","author":"Xu","year":"2004","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ecl.2013.05.009_bib33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ecl.2013.05.009_bib34","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/01.JGP.0000231780.44684.7e","article-title":"Vascular cognitive impairment","volume":"14","author":"O'Brien","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000337428","article-title":"Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study","volume":"38","author":"Wang","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.ecl.2013.05.009_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S104161020200844X","article-title":"Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old","volume":"14","author":"Hassing","year":"2002","journal-title":"Int Psychogeriatr"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000064928","article-title":"Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging","volume":"14","author":"MacKnight","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"10","key":"10.1016\/j.ecl.2013.05.009_bib38","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1212\/01.wnl.0000324925.95210.6d","article-title":"Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology","volume":"71","author":"Beeri","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ecl.2013.05.009_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nrneurol.2009.72","article-title":"Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease","volume":"5","author":"Kalaria","year":"2009","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.ecl.2013.05.009_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1047-2797(02)00464-7","article-title":"Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study","volume":"13","author":"Wu","year":"2003","journal-title":"Ann Epidemiol"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","article-title":"Insulin in the brain: there and back again","volume":"136","author":"Banks","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ecl.2013.05.009_bib42","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/j.1464-5491.2011.03464.x","article-title":"Insulin resistance and pathological brain ageing","volume":"28","author":"Cholerton","year":"2011","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.wad.0000213866.86934.7e","article-title":"Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications","volume":"20","author":"Craft","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5651","key":"10.1016\/j.ecl.2013.05.009_bib44","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1126\/science.1092952","article-title":"Insulin signaling in health and disease","volume":"302","author":"White","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2337\/diab.45.1.86","article-title":"Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs","volume":"45","author":"Baura","year":"1996","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2013.05.009_bib46","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2337\/dc11-2075","article-title":"Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly","volume":"35","author":"Benedict","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archneurol.2010.225","article-title":"Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes","volume":"68","author":"Baker","year":"2011","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0031-9384(99)00220-6","article-title":"Intracerebroventricular insulin enhances memory in a passive-avoidance task","volume":"68","author":"Park","year":"2000","journal-title":"Physiol Behav"},{"issue":"6","key":"10.1016\/j.ecl.2013.05.009_bib49","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0306-4530(02)00087-2","article-title":"Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype","volume":"28","author":"Craft","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1016\/j.ecl.2013.05.009_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.ecl.2013.05.009_bib51","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3233\/JAD-122308","article-title":"Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease","volume":"35","author":"Claxton","year":"2013","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-2012-120202","article-title":"Insulin and sex interactions in older adults with mild cognitive impairment","volume":"31","author":"Cholerton","year":"2012","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol Aging"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2013.05.009_bib56","first-page":"S263","article-title":"Insulin and Alzheimer's disease: untangling the web","volume":"33","author":"Craft","year":"2013","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.ecl.2013.05.009_bib57","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1212\/01.WNL.0000065916.25128.25","article-title":"Insulin increases CSF Abeta42 levels in normal older adults","volume":"60","author":"Watson","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ecl.2013.05.009_bib58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0306-4522(99)00458-3","article-title":"The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein","volume":"95","author":"Boyt","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.ecl.2013.05.009_bib59","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.2000.tb06371.x","article-title":"Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype","volume":"903","author":"Craft","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ecl.2013.05.009_bib60","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1749-6632.2000.tb05571.x","article-title":"A\u00a0perspective on inflammation in Alzheimer's disease","volume":"924","author":"Rogers","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11892-002-0019-0","article-title":"Endothelium, inflammation, and diabetes","volume":"2","author":"Dandona","year":"2002","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib62","doi-asserted-by":"crossref","first-page":"E234","DOI":"10.1152\/ajpendo.00274.2003","article-title":"Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue","volume":"286","author":"Krogh-Madsen","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2013.05.009_bib63","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/archneur.62.10.noc50112","article-title":"Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults","volume":"62","author":"Fishel","year":"2005","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI10843","article-title":"Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists","volume":"106","author":"Olefsky","year":"2000","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1523\/JNEUROSCI.20-02-00558.2000","article-title":"Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists","volume":"20","author":"Combs","year":"2000","journal-title":"J\u00a0Neurosci"},{"issue":"6","key":"10.1016\/j.ecl.2013.05.009_bib66","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1074\/jbc.272.6.3406","article-title":"Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs","volume":"272","author":"Lehmann","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"15","key":"10.1016\/j.ecl.2013.05.009_bib67","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1523\/JNEUROSCI.20-15-05709.2000","article-title":"Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease","volume":"20","author":"Lim","year":"2000","journal-title":"J\u00a0Neurosci"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbr.2010.08.002","article-title":"Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status","volume":"216","author":"Rodriguez-Rivera","year":"2011","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.expneurol.2006.01.018","article-title":"Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice","volume":"199","author":"Pedersen","year":"2006","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11481-011-9282-7","article-title":"Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP\/PS1 mice","volume":"7","author":"O'Reilly","year":"2012","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"issue":"7","key":"10.1016\/j.ecl.2013.05.009_bib71","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/npp.2010.32","article-title":"Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology","volume":"35","author":"Escribano","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"37","key":"10.1016\/j.ecl.2013.05.009_bib72","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1523\/JNEUROSCI.3348-08.2008","article-title":"Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist","volume":"28","author":"Nicolakakis","year":"2008","journal-title":"J\u00a0Neurosci"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib73","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3233\/JAD-2012-111661","article-title":"Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease","volume":"30","author":"Searcy","year":"2012","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.ecl.2013.05.009_bib74","first-page":"950","article-title":"Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study","volume":"13","author":"Watson","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib75","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"10.1016\/j.ecl.2013.05.009_bib77","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1532-5415.2009.02067.x","article-title":"Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus","volume":"57","author":"Hanyu","year":"2009","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"9","key":"10.1016\/j.ecl.2013.05.009_bib79","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","article-title":"Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease","volume":"32","author":"Sato","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A\u00a0randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib81","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jpba.2010.10.008","article-title":"Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia","volume":"54","author":"Sheu","year":"2011","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2007-11108","article-title":"Rosiglitazone induces mitochondrial biogenesis in mouse brain","volume":"11","author":"Strum","year":"2007","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.ecl.2013.05.009_bib83","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1210\/en.2007-1553","article-title":"Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status","volume":"149","author":"Festuccia","year":"2008","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib84","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00280-013-2084-2","article-title":"The PPARgamma agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model","volume":"71","author":"Grommes","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib85","first-page":"29","article-title":"Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys","volume":"47","author":"Maeshiba","year":"1997","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib86","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijcard.2009.01.064","article-title":"Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials","volume":"143","author":"Mannucci","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ecl.2013.05.009_bib87","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/B978-0-12-381517-0.00013-8","article-title":"The role of GLP-1 in neuronal activity and neurodegeneration","volume":"84","author":"Holscher","year":"2010","journal-title":"Vitam Horm"},{"issue":"2","key":"10.1016\/j.ecl.2013.05.009_bib88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.abb.2004.05.005","article-title":"Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in\u00a0vivo antidiabetic actions following substitution of Ala8\/Ala2 with 2-aminobutyric acid","volume":"428","author":"Green","year":"2004","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib89","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","article-title":"The effect of glucagon-like peptide 1 on cardiovascular risk","volume":"9","author":"Sivertsen","year":"2012","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.ecl.2013.05.009_bib90","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/jcbfm.2012.118","article-title":"Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia","volume":"32","author":"Gejl","year":"2012","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib91","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.ecl.2013.05.009_bib92","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2013.05.009_bib93","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/jnnp.2003.012096","article-title":"Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease","volume":"75","author":"Tian","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.ecl.2013.05.009_bib94","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","article-title":"Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide","volume":"62","author":"Labuzek","year":"2010","journal-title":"Pharmacol Rep"},{"issue":"8","key":"10.1016\/j.ecl.2013.05.009_bib95","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.2337\/diabetes.54.8.2404","article-title":"Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin","volume":"54","author":"Kitabchi","year":"2005","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ecl.2013.05.009_bib96","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.ecl.2013.05.009_bib97","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1073\/pnas.0807991106","article-title":"Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"50","key":"10.1016\/j.ecl.2013.05.009_bib98","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.ecl.2013.05.009_bib99","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pbb.2012.03.002","article-title":"Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice","volume":"101","author":"Li","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.ecl.2013.05.009_bib100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbr.2011.01.022","article-title":"Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes","volume":"220","author":"Bhutada","year":"2011","journal-title":"Behav Brain Res"},{"issue":"11\u201312","key":"10.1016\/j.ecl.2013.05.009_bib101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.lfs.2012.08.017","article-title":"Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats","volume":"91","author":"Pintana","year":"2012","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.ecl.2013.05.009_bib102","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2337\/dc09-2030","article-title":"Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment","volume":"33","author":"Abbatecola","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2013.05.009_bib103","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.ecl.2013.05.009_bib104","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JAD-2011-101524","article-title":"Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin","volume":"24","author":"Hsu","year":"2011","journal-title":"J\u00a0Alzheimers Dis"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852913000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852913000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:38:58Z","timestamp":1760175538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852913000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0889852913000480"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2013.05.009","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 Diabetes and Cognitive Compromise","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2013.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}